DJIA 17,087.46 0.83 0.00%
NASDAQ 4,475.23 1.53 0.03%
S&P 500 1,987.88 0.87 0.04%
market minute promo

Peregrine Pharmaceuticals (NASDAQ: PPHM)

1.58 0.01 (0.32%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PPHM $1.58 0.32%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.59
Previous Close $1.57
Daily Range $1.56 - $1.62
52-Week Range $1.16 - $3.18
Market Cap $282.3M
P/E Ratio -7.14
Dividend (Yield) $0.00 (0.0%)
Volume 1,132,737
Average Daily Volume 1,269,238
Current FY EPS -$0.28

Sector

Healthcare

Industry

Drugs

Peregrine Pharmaceuticals (PPHM) Description

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases. Website: http://www.peregrineinc.com/

News & Commentary Rss Feed

These 5 Cancer Immunotherapy Companies All Have 1 Thing in Common

Cancer immunotherapies are all the rage on Wall Street, but these five immunotherapy-focused companies all have one big thing in common.

Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog

Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q4 2014 Results - Earnings Call Transcript

Earnings Reaction History: Peregrine Pharmaceuticals Corporation, 50.0% Follow-Through Indicator, 16

Earnings Reaction History: Peregrine Pharmaceuticals Corporation, 50.0% Follow-Through Indicator, 16.5% Sensitive

After-Hours Earnings Report for July 14, 2014 : OZRK, WTFC, PPHM, MILL, SAR, LEDS

After-Hours Earnings Report for July 14, 2014 : OZRK, WTFC, PPHM, MILL, SAR, LEDS

Earnings Scheduled For July 14, 2014

Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack

Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog

Peregrine Pharmaceuticals Announces Investigator-Sponsored Trial Combining Immunotherapy Bavituximab

Peregrine Pharmaceuticals Announces Investigator-Sponsored Trial Combining Immunotherapy Bavituximab, Ipilimumab

UPDATE: Peregrine Pharma Reports Data on Bavituximab Presented at AACR Validates Immune-Stimulatory

UPDATE: Peregrine Pharma Reports Data on Bavituximab Presented at AACR Validates Immune-Stimulatory Mechanism of Action

Morning Market Movers

See More PPHM News...

PPHM's Top Competitors

PPHM $1.58 (0.32%)
Current stock: PPHM
AMGN $122.23 (0.18%)
Current stock: AMGN
GILD $90.55 (0.23%)
Current stock: GILD
BIIB $336.78 (-0.24%)
Current stock: BIIB